Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)

Trial Profile

Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Primary endpoint (Objective clinical response rate) has not been met, according to results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results assessing efficacy and tolerability of paclitaxel in patients with advanced non-small-cell lung cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 28 Dec 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top